Darunavir: A Critical Review of Its Properties, Use and Drug Interactions

Detalhes bibliográficos
Autor(a) principal: Ruela Correa, Josilene Chaves [UNESP]
Data de Publicação: 2012
Outros Autores: D'Arcy, Deirdre M., dos Reis Serra, Cristina Helena, Salgado, Hérida Regina Nunes [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1159/000339862
http://hdl.handle.net/11449/7862
Resumo: Darunavir is a synthetic nonpeptidic protease inhibitor which has been shown to be extremely potent against wildtype HIV as well as a large panel of PI-resistant clinical isolates and shows a high genetic barrier to the development of antiretroviral resistance. The treatment of HIV/AIDS requires combinations of multiple antiretroviral drugs. In addition, patients frequently need to coadminister other medications for reasons including the prevention or treatment of opportunistic infections, treatment of concomitant illnesses and management of antiretroviral side effects. Drug interactions have been observed between darunavir and other drugs. New and more comprehensive drug interaction studies will be required since the increase in life expectancy of patients often brings new comorbidities and the concomitant use of different drugs. This paper discusses the impact of the use of darunavir in the treatment of HIV-infected patients, its pharmacological and physical-chemical properties, its drug interactions, and challenges that remain in order to ensure safety and compliance of treatment. Copyright (C) 2012 S. Karger AG, Basel
id UNSP_1badd2e02106ce17c4e60c06d0e20985
oai_identifier_str oai:repositorio.unesp.br:11449/7862
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Darunavir: A Critical Review of Its Properties, Use and Drug InteractionsDarunavirHuman immunodeficiency virusAcquired immune deficiency syndromeClinical pharmacokineticsDrug interactionsBiopharmaceutics classification systemDarunavir is a synthetic nonpeptidic protease inhibitor which has been shown to be extremely potent against wildtype HIV as well as a large panel of PI-resistant clinical isolates and shows a high genetic barrier to the development of antiretroviral resistance. The treatment of HIV/AIDS requires combinations of multiple antiretroviral drugs. In addition, patients frequently need to coadminister other medications for reasons including the prevention or treatment of opportunistic infections, treatment of concomitant illnesses and management of antiretroviral side effects. Drug interactions have been observed between darunavir and other drugs. New and more comprehensive drug interaction studies will be required since the increase in life expectancy of patients often brings new comorbidities and the concomitant use of different drugs. This paper discusses the impact of the use of darunavir in the treatment of HIV-infected patients, its pharmacological and physical-chemical properties, its drug interactions, and challenges that remain in order to ensure safety and compliance of treatment. Copyright (C) 2012 S. Karger AG, BaselFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Fundação para o Desenvolvimento da UNESP (FUNDUNESP)PADC-UNESPUniv Estadual Paulista, Sch Pharmaceut Sci, Drugs & Med Qual Control Lab, BR-14801902 Araraquara, BrazilUniv São Paulo, Sch Pharmaceut Sci, São Paulo, BrazilTrinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, IrelandUniv Estadual Paulista, Sch Pharmaceut Sci, Drugs & Med Qual Control Lab, BR-14801902 Araraquara, BrazilKargerUniversidade Estadual Paulista (Unesp)Universidade de São Paulo (USP)Trinity Coll DublinRuela Correa, Josilene Chaves [UNESP]D'Arcy, Deirdre M.dos Reis Serra, Cristina HelenaSalgado, Hérida Regina Nunes [UNESP]2014-05-20T13:24:55Z2014-05-20T13:24:55Z2012-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article102-109http://dx.doi.org/10.1159/000339862Pharmacology. Basel: Karger, v. 90, n. 1-2, p. 102-109, 2012.0031-7012http://hdl.handle.net/11449/786210.1159/000339862WOS:000307156100011Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengPharmacology1.5380,502info:eu-repo/semantics/openAccess2024-06-24T13:45:18Zoai:repositorio.unesp.br:11449/7862Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T14:57:42.307733Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Darunavir: A Critical Review of Its Properties, Use and Drug Interactions
title Darunavir: A Critical Review of Its Properties, Use and Drug Interactions
spellingShingle Darunavir: A Critical Review of Its Properties, Use and Drug Interactions
Ruela Correa, Josilene Chaves [UNESP]
Darunavir
Human immunodeficiency virus
Acquired immune deficiency syndrome
Clinical pharmacokinetics
Drug interactions
Biopharmaceutics classification system
title_short Darunavir: A Critical Review of Its Properties, Use and Drug Interactions
title_full Darunavir: A Critical Review of Its Properties, Use and Drug Interactions
title_fullStr Darunavir: A Critical Review of Its Properties, Use and Drug Interactions
title_full_unstemmed Darunavir: A Critical Review of Its Properties, Use and Drug Interactions
title_sort Darunavir: A Critical Review of Its Properties, Use and Drug Interactions
author Ruela Correa, Josilene Chaves [UNESP]
author_facet Ruela Correa, Josilene Chaves [UNESP]
D'Arcy, Deirdre M.
dos Reis Serra, Cristina Helena
Salgado, Hérida Regina Nunes [UNESP]
author_role author
author2 D'Arcy, Deirdre M.
dos Reis Serra, Cristina Helena
Salgado, Hérida Regina Nunes [UNESP]
author2_role author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (Unesp)
Universidade de São Paulo (USP)
Trinity Coll Dublin
dc.contributor.author.fl_str_mv Ruela Correa, Josilene Chaves [UNESP]
D'Arcy, Deirdre M.
dos Reis Serra, Cristina Helena
Salgado, Hérida Regina Nunes [UNESP]
dc.subject.por.fl_str_mv Darunavir
Human immunodeficiency virus
Acquired immune deficiency syndrome
Clinical pharmacokinetics
Drug interactions
Biopharmaceutics classification system
topic Darunavir
Human immunodeficiency virus
Acquired immune deficiency syndrome
Clinical pharmacokinetics
Drug interactions
Biopharmaceutics classification system
description Darunavir is a synthetic nonpeptidic protease inhibitor which has been shown to be extremely potent against wildtype HIV as well as a large panel of PI-resistant clinical isolates and shows a high genetic barrier to the development of antiretroviral resistance. The treatment of HIV/AIDS requires combinations of multiple antiretroviral drugs. In addition, patients frequently need to coadminister other medications for reasons including the prevention or treatment of opportunistic infections, treatment of concomitant illnesses and management of antiretroviral side effects. Drug interactions have been observed between darunavir and other drugs. New and more comprehensive drug interaction studies will be required since the increase in life expectancy of patients often brings new comorbidities and the concomitant use of different drugs. This paper discusses the impact of the use of darunavir in the treatment of HIV-infected patients, its pharmacological and physical-chemical properties, its drug interactions, and challenges that remain in order to ensure safety and compliance of treatment. Copyright (C) 2012 S. Karger AG, Basel
publishDate 2012
dc.date.none.fl_str_mv 2012-01-01
2014-05-20T13:24:55Z
2014-05-20T13:24:55Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1159/000339862
Pharmacology. Basel: Karger, v. 90, n. 1-2, p. 102-109, 2012.
0031-7012
http://hdl.handle.net/11449/7862
10.1159/000339862
WOS:000307156100011
url http://dx.doi.org/10.1159/000339862
http://hdl.handle.net/11449/7862
identifier_str_mv Pharmacology. Basel: Karger, v. 90, n. 1-2, p. 102-109, 2012.
0031-7012
10.1159/000339862
WOS:000307156100011
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Pharmacology
1.538
0,502
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 102-109
dc.publisher.none.fl_str_mv Karger
publisher.none.fl_str_mv Karger
dc.source.none.fl_str_mv Web of Science
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128441812254720

Registros relacionados